Stock BLU BELLUS HEALTH
Add to a list
To use this feature you must be a member
Log inSign up

Financials BELLUS Health

Equities

BLU

CA07987C2040

Biotechnology & Medical Research

Market Closed - Toronto S.E.
Other stock markets
 04:00:00 2023-06-29 pm EDT 		5-day change 1st Jan Change
19.48 CAD -0.10% Intraday chart for BELLUS Health -.--% -.--%
2023 BELLUS Health Inc.(TSX:BLU) dropped from S&P/TSX Capped Composite Index CI
2023 BELLUS Health Inc.(TSX:BLU) dropped from S&P/TSX Completion Index CI

Valuation

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Capitalization 1 35.12 117.3 417.9 235.6 831.3 1,034
Enterprise Value (EV) 2 11.24 68.38 301.3 137.8 583.4 698.4
P/E ratio -10.8 x -9.95 x -10.4 x -5.59 x -8.96 x -12.4 x
Yield - - - - - -
Capitalization / Revenue 213 x 3,351 x 11,941 x 15,704 x 51,957 x 64,637 x
EV / Revenue 68.1 x 1,954 x 8,608 x 9,187 x 36,461 x 43,652 x
EV / EBITDA - - - - - -9,000,892 x
EV / FCF -2.57 x -16.1 x -21.4 x -7.29 x -18.4 x -14.5 x
FCF Yield -39% -6.22% -4.66% -13.7% -5.43% -6.92%
Price to Book 1.34 x 2.32 x 3.63 x 1.6 x 2.93 x 2.65 x
Nbr of stocks (in thousands) 33,194 43,622 55,379 78,337 103,353 126,562
Reference price 3 1.058 2.689 7.547 3.007 8.043 8.172
Announcement Date 2/21/18 2/21/19 2/27/20 2/25/21 2/23/22 3/23/23
1USD in Million2CAD in Million3USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales 1 0.165 0.035 0.035 0.015 0.016 0.016
EBITDA - - - - - -77.6
EBIT 1 -5.685 -9.906 -34.1 -32.94 -73.28 -77.88
Operating Margin -3,445.45% -28,302.86% -97,428.57% -219,613.33% -458,025% -486,768.75%
Earnings before Tax (EBT) 1 -1.813 -9.084 -34.47 -31.76 -71.42 -76.02
Net income 1 -1.874 -9.084 -34.47 -31.76 -71.22 -76.08
Net margin -1,135.76% -25,954.29% -98,474.29% -211,713.33% -445,150% -475,500%
EPS 2 -0.0982 -0.2702 -0.7267 -0.5380 -0.8980 -0.6595
Free Cash Flow 1 -4.378 -4.253 -14.05 -18.91 -31.66 -48.3
FCF margin -2,653.33% -12,152.5% -40,155% -126,067.5% -197,861.72% -301,883.59%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 2/21/18 2/21/19 2/27/20 2/25/21 2/23/22 3/23/23
1CAD in Million2CAD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 - - - - - -
Net Cash position 1 23.9 48.9 117 97.8 248 336
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -4.38 -4.25 -14.1 -18.9 -31.7 -48.3
ROE (net income / shareholders' equity) -10.8% -23.6% -41.6% -26.9% -32.4% -22.3%
ROA (Net income/ Total Assets) -18.7% -15.1% -23.9% -16.5% -19.8% -13.6%
Assets 1 10.04 60.01 144.3 192.4 359.8 560.6
Book Value Per Share 2 0.7900 1.160 2.080 1.880 2.740 3.090
Cash Flow per Share 2 0.2300 0.3400 0.4400 0.6200 1.410 0.6900
Capex - - - - - -
Capex / Sales - - - - - -
Announcement Date 2/21/18 2/21/19 2/27/20 2/25/21 2/23/22 3/23/23
1CAD in Million2CAD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
BELLUS HEALTH Stock BELLUS Health
-.--% 1.87B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. BLU Stock
  4. Financials BELLUS Health